Cargando…
The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice
BACKGROUND: In Duchenne muscular dystrophy (DMD), loss of the membrane stabilizing protein dystrophin results in myofiber damage. Microinjury to dystrophic myofibers also causes secondary imbalances in sarcolemmic ion permeability and resting membrane potential, which modifies excitation-contraction...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699610/ https://www.ncbi.nlm.nih.gov/pubmed/23843959 http://dx.doi.org/10.1371/journal.pone.0066617 |
_version_ | 1782275423035457536 |
---|---|
author | Sali, Arpana Many, Gina M. Gordish-Dressman, Heather van der Meulen, Jack H. Phadke, Aditi Spurney, Christopher F. Cnaan, Avital Hoffman, Eric P. Nagaraju, Kanneboyina |
author_facet | Sali, Arpana Many, Gina M. Gordish-Dressman, Heather van der Meulen, Jack H. Phadke, Aditi Spurney, Christopher F. Cnaan, Avital Hoffman, Eric P. Nagaraju, Kanneboyina |
author_sort | Sali, Arpana |
collection | PubMed |
description | BACKGROUND: In Duchenne muscular dystrophy (DMD), loss of the membrane stabilizing protein dystrophin results in myofiber damage. Microinjury to dystrophic myofibers also causes secondary imbalances in sarcolemmic ion permeability and resting membrane potential, which modifies excitation-contraction coupling and increases proinflammatory/apoptotic signaling cascades. Although glucocorticoids remain the standard of care for the treatment of DMD, there is a need to investigate the efficacy of other pharmacological agents targeting the involvement of imbalances in ion flux on dystrophic pathology. METHODOLOGY/PRINCIPAL FINDINGS: We designed a preclinical trial to investigate the effects of lansoprazole (LANZO) administration, a proton pump inhibitor, on the dystrophic muscle phenotype in dystrophin deficient (mdx) mice. Eight to ten week-old female mice were assigned to one of four treatment groups (n = 12 per group): (1) vehicle control; (2) 5 mg/kg/day LANZO; (3) 5 mg/kg/day prednisolone; and (4) combined treatment of 5 mg/kg/day prednisolone (PRED) and 5 mg/kg/day LANZO. Treatment was administered orally 5 d/wk for 3 months. At the end of the study, behavioral (Digiscan) and functional outcomes (grip strength and Rotarod) were assessed prior to sacrifice. After sacrifice, body, tissue and organ masses, muscle histology, in vitro muscle force, and creatine kinase levels were measured. Mice in the combined treatment groups displayed significant reductions in the number of degenerating muscle fibers and number of inflammatory foci per muscle field relative to vehicle control. Additionally, mice in the combined treatment group displayed less of a decline in normalized forelimb and hindlimb grip strength and declines in in vitro EDL force after repeated eccentric contractions. CONCLUSIONS/SIGNIFICANCE: Together our findings suggest that combined treatment of LANZO and prednisolone attenuates some components of dystrophic pathology in mdx mice. Our findings warrant future investigation of the clinical efficacy of LANZO and prednisolone combined treatment regimens in dystrophic pathology. |
format | Online Article Text |
id | pubmed-3699610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36996102013-07-10 The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice Sali, Arpana Many, Gina M. Gordish-Dressman, Heather van der Meulen, Jack H. Phadke, Aditi Spurney, Christopher F. Cnaan, Avital Hoffman, Eric P. Nagaraju, Kanneboyina PLoS One Research Article BACKGROUND: In Duchenne muscular dystrophy (DMD), loss of the membrane stabilizing protein dystrophin results in myofiber damage. Microinjury to dystrophic myofibers also causes secondary imbalances in sarcolemmic ion permeability and resting membrane potential, which modifies excitation-contraction coupling and increases proinflammatory/apoptotic signaling cascades. Although glucocorticoids remain the standard of care for the treatment of DMD, there is a need to investigate the efficacy of other pharmacological agents targeting the involvement of imbalances in ion flux on dystrophic pathology. METHODOLOGY/PRINCIPAL FINDINGS: We designed a preclinical trial to investigate the effects of lansoprazole (LANZO) administration, a proton pump inhibitor, on the dystrophic muscle phenotype in dystrophin deficient (mdx) mice. Eight to ten week-old female mice were assigned to one of four treatment groups (n = 12 per group): (1) vehicle control; (2) 5 mg/kg/day LANZO; (3) 5 mg/kg/day prednisolone; and (4) combined treatment of 5 mg/kg/day prednisolone (PRED) and 5 mg/kg/day LANZO. Treatment was administered orally 5 d/wk for 3 months. At the end of the study, behavioral (Digiscan) and functional outcomes (grip strength and Rotarod) were assessed prior to sacrifice. After sacrifice, body, tissue and organ masses, muscle histology, in vitro muscle force, and creatine kinase levels were measured. Mice in the combined treatment groups displayed significant reductions in the number of degenerating muscle fibers and number of inflammatory foci per muscle field relative to vehicle control. Additionally, mice in the combined treatment group displayed less of a decline in normalized forelimb and hindlimb grip strength and declines in in vitro EDL force after repeated eccentric contractions. CONCLUSIONS/SIGNIFICANCE: Together our findings suggest that combined treatment of LANZO and prednisolone attenuates some components of dystrophic pathology in mdx mice. Our findings warrant future investigation of the clinical efficacy of LANZO and prednisolone combined treatment regimens in dystrophic pathology. Public Library of Science 2013-07-02 /pmc/articles/PMC3699610/ /pubmed/23843959 http://dx.doi.org/10.1371/journal.pone.0066617 Text en © 2013 Sali et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Sali, Arpana Many, Gina M. Gordish-Dressman, Heather van der Meulen, Jack H. Phadke, Aditi Spurney, Christopher F. Cnaan, Avital Hoffman, Eric P. Nagaraju, Kanneboyina The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice |
title | The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice |
title_full | The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice |
title_fullStr | The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice |
title_full_unstemmed | The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice |
title_short | The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice |
title_sort | proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699610/ https://www.ncbi.nlm.nih.gov/pubmed/23843959 http://dx.doi.org/10.1371/journal.pone.0066617 |
work_keys_str_mv | AT saliarpana theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT manyginam theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT gordishdressmanheather theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT vandermeulenjackh theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT phadkeaditi theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT spurneychristopherf theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT cnaanavital theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT hoffmanericp theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT nagarajukanneboyina theprotonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT saliarpana protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT manyginam protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT gordishdressmanheather protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT vandermeulenjackh protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT phadkeaditi protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT spurneychristopherf protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT cnaanavital protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT hoffmanericp protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice AT nagarajukanneboyina protonpumpinhibitorlansoprazoleimprovestheskeletalphenotypeindystrophindeficientmdxmice |